How a sedative marketed as harmless triggered a global medical tragedy and regulatory revolution.

How a sedative marketed as harmless triggered a global medical tragedy and regulatory revolution.
Image: Intellect (generated)

In short: Developed in the 1950s as a supposedly safe sedative, thalidomide became a global disaster when it caused severe fetal malformations. The tragedy exposed critical gaps in drug testing, forcing governments to overhaul how they regulate medicine and forever changing the relationship between the pharmaceutical industry, safety standards, and public health.

In the mid-1950s, the West German company Chemie Grünenthal developed thalidomide, intending it to be a harmless sedative and antiemetic. Because researchers found it nearly impossible to deliver a lethal dose to test animals, the drug was marketed as exceptionally safe. By the mid-1950s, it was sold in 46 countries under at least 37 different names, often over-the-counter. It was widely prescribed for conditions ranging from colds to morning sickness, with advertisements even claiming it could be taken by pregnant women without any adverse effects.

The disaster unfolded because no tests had been conducted on pregnant subjects, and scientists at the time did not realize drugs could cross the placental barrier to impact a fetus. Between 20 and 37 days after conception, the drug caused catastrophic developmental impairments, including limb differences, sight and hearing loss, and internal organ damage. It is estimated that over 10,000 babies were affected worldwide, with approximately half dying shortly after birth. The link was finally made public in 1961 by Australian doctor William McBride, leading to the drug's withdrawal.

The tragedy fundamentally transformed global drug regulation. In the United States, the FDA had rejected the drug, largely due to the skepticism of pharmacologist Frances Oldham Kelsey, who demanded clinical evidence that the company could not provide. Following the scandal, many nations implemented much stricter clinical testing and side-effect reporting requirements. Today, thalidomide is used under highly controlled conditions to treat specific cancers and leprosy, but its history remains a stark reminder of the necessity for rigorous, evidence-based safety protocols in the pharmaceutical industry.

Opens the Intellect+ feed with this card first. Swipe up for the next one.

Sources

To cite this card, link to https://intellectplus.co.uk/app/technology-thalidomide.

How we source, check and correct cards: Editorial standards.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

Finding something worth knowing…